{"@context":{"@vocab":"https://schema.org/"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/fda/warning-letters/check?name=Re-Gen%20Active%20Lab%2C%20Inc.","name":"Re-Gen Active Lab, Inc.","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://creativecommons.org/publicdomain/zero/1.0/","primary_source":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters","generated_at":"2026-11-14T20:33:36.568Z"},"count":1,"matches":[{"id":"42a0692e37458cd3","posted_date":"2022-06-28","letter_issue_date":"2022-05-27","company_name":"Re-Gen Active Lab, Inc.","issuing_office":"Office of Biological Products Operations – Division 2","subject":"Deviations/CFR/Regulations for Human Cells, Tissues & Cellular Products (HCT/Ps)","canonical_url":"https://api.morvs.ai/fda-warning/42a0692e37458cd3"}]}